Temsirolimus in Recurrent Primary Central Nervous System (CNS) Lymphoma
Status:
Unknown status
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This is an open-label trial investigating the efficacy of temsirolimus in recurrent or
refractory primary CNS lymphoma (PCNSL) after initial chemotherapy with a high-dose
methotrexate containing regimen. 37 patients are planned to be treated with weekly infusions
of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a
maximum of 12 months. The trial is designed in two stages, if less than one of the first 12
patients responds to treatment, the trial is stopped. In addition to efficacy, safety and
penetration of temsirolimus into the cerebrospinal fluid will be investigated.